A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...
NEW research highlights the utility of the PRECISE-DAPT score in predicting gastrointestinal (GI) bleeding risk in patients undergoing dual antiplatelet therapy (DAPT) after percutaneous coronary ...
The HeartBeam system is currently under review with the FDA. “The data presentations at AHA are a testament to HeartBeam’s dedication to building a robust body of clinical evidence to support our ...